New medicinal product from GEROPHARM for the treatment of chronic prostatitis and benign prostatic hyperplasia
GEROPHARM has launched in the Russian market an innovator medicinal product for the treatment of chronic prostatitis and benign prostatic hyperplasia. This is a formulation with a combination of two active ingredients: prostate extract and tamsulosin hydrochloride. Formerly, tamsulosin-based products from other manufacturers had capsule and tablet presentations, and these compounds’ combinations could be achieved only by a concurrent administration of several medications.
Benign prostatic hyperplasia and chronic prostatitis are very common urogenital diseases in men. Benign prostatic hyperplasia affects one in 10 men above 40 years of age and fifty percent of men aged 50 to 60 years, while by the age of 80 years, the prevalence is 80 %. Although prostatic tissue hyperplasia may be considered normal, this condition is often accompanied by various urological disorders. Among them are trouble voiding the bladder, frequent urination urges, and pain. The disease may provoke such complications as chronic prostatitis and urine calculus. Chronic prostatitis affects an even larger proportion of men: 30 % to 80 % in all age groups above 30 years of age. Both of these disorders also affect the erectile function.
Various medications are used to treat these diseases, including those containing prostate extract and tamsulosin hydrochloride. Now, a novel innovator product is available in Russia, in which both these active ingredients are combined. The Russian company GEROPHARM has been granted a patent for this combination and launched the medicinal product in the Russian market. This medicinal product will make the time to the effect onset shorter and mitigate the urological symptoms of benign prostatic hyperplasia, both as an underlying disease and complicated by chronic prostatitis. The novel medicinal product is the first domestic tamsulosin preparation in the suppository presentation.
The product also has a muscle-relaxing effect that opens more opportunities for the treatment of kidney stone disease and post-surgery recovery of patients. The lower third of the ureter is its narrowest part. This is where stones get stuck most often, even the smallest ones. Tamsulosin helps manage it. With the muscular tunic relaxed, stones up to 6 mm in size, sitting in the urethra, can be painlessly and fast eliminated from the body. In the post-surgery period, this mechanism is capable of easing the discomfort from the elimination of dusted stones through the urethra.GEROPHARM has launched in the Russian market an innovator medicinal product for the treatment of chronic prostatitis and benign prostatic hyperplasia. This is a formulation with a combination of two active ingredients: prostate extract and tamsulosin hydrochloride. Formerly, tamsulosin-based products from other manufacturers had capsule and tablet presentations, and these compounds’ combinations could be achieved only by a concurrent administration of several medications.
Benign prostatic hyperplasia and chronic prostatitis are very common urogenital diseases in men. Benign prostatic hyperplasia affects one in 10 men above 40 years of age and fifty percent of men aged 50 to 60 years, while by the age of 80 years, the prevalence is 80 %. Although prostatic tissue hyperplasia may be considered normal, this condition is often accompanied by various urological disorders. Among them are trouble voiding the bladder, frequent urination urges, and pain. The disease may provoke such complications as chronic prostatitis and urine calculus. Chronic prostatitis affects an even larger proportion of men: 30 % to 80 % in all age groups above 30 years of age. Both of these disorders also affect the erectile function.
Various medications are used to treat these diseases, including those containing prostate extract and tamsulosin hydrochloride. Now, a novel innovator product is available in Russia, in which both these active ingredients are combined. The Russian company GEROPHARM has been granted a patent for this combination and launched the medicinal product in the Russian market. This medicinal product will make the time to the effect onset shorter and mitigate the urological symptoms of benign prostatic hyperplasia, both as an underlying disease and complicated by chronic prostatitis. The novel medicinal product is the first domestic tamsulosin preparation in the suppository presentation.
The product also has a muscle-relaxing effect that opens more opportunities for the treatment of kidney stone disease and post-surgery recovery of patients. The lower third of the ureter is its narrowest part. This is where stones get stuck most often, even the smallest ones. Tamsulosin helps manage it. With the muscular tunic relaxed, stones up to 6 mm in size, sitting in the urethra, can be painlessly and fast eliminated from the body. In the post-surgery period, this mechanism is capable of easing the discomfort from the elimination of dusted stones through the urethra.
